Here's how these stocks missed out on a positive day for the market.
News & Analysis: Zafgen
News of an FDA clinical hold zaps Zafgen's share price.
Can these high-flying biotech stocks keep up their momentum?
The early-stage biopharma announced the pricing of a common stock offering.
The biopharma announced full-year 2017 results and several business updates.
Shares took a nose dive on Monday after an investment firm published a short report on the company.
These stocks led the broader market lower. Find out why.
The FDA puts a clinical hold on the biotech's lead drug.
It's all relative.
Someone knows something, but no one is talking.